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Background: The Global Asthma Physician and Patient (GAPP)
survey evaluated the perceptions of both physicians and patients on
the management of asthma. Here we present the results from the
United States (US) subpopulation of the GAPP survey.
Methods: The GAPP Survey was a large, global study (physicians,
n 1733; patients, n 1726; interviews, n 3459). In the US, 208
adults (aged 18 years) with asthma and 224 physicians were
recruited. Respondents were questioned using self-administered on-
line interviews with close-ended questionnaires.
Results: Physician and patient responses were found to differ in
regard to perception of time spent on asthma education, awareness
of disease symptoms and their severity, asthma medication side
effects, and adherence to treatment and the consequence of nonad-
herence. Comparison of the US findings with the global GAPP
survey results suggest the US physician-patient partnership com-
pared reasonably well with the other countries in the survey. Both
patients and physicians cited a need for new asthma medication.
Conclusions: Similar to the global GAPP survey, the US-specific
findings indicate that in general there is a lack of asthma control,
poor adherence to therapy, and room for improvement in patient-
physician communication and partnership in treating asthma.
Key Words: asthma, inhaled corticosteroids, side-effects, Global
Asthma Physician and Patient (GAPP) Survey, compliance,
asthma management, asthma education
(WAO Journal 2009; 2:303–313)
Asthma is a major public health problem that affects anestimated 20 million people in the United States (US),
with the prevalence expected to continue to rise in the
future.1–3 Asthma is characterized by airway inflammation
and hyper-responsiveness that lead to symptoms such as
coughing, wheezing, breathlessness and chest tightness.1 The
impact of asthma on patients can be considerable,4 and the
chronic characteristic of the disease may require long-term
controller therapy to help manage symptoms and sustain lung
function.1 Inadequately controlled asthma can result in sub-
stantial absence from school or lost productivity at work, and
a reduced quality of life.2,5–7
Effective medications are available to help control the
persistent symptoms of asthma and appropriate intervention
with these is an essential part of any asthma management
program.1 Inhaled corticosteroids (ICS) are the most effective
controller therapy currently available and are recommended
by the international (GINA) and national (NAEPP/NHLBI)
guidelines as the first-line treatment for persistent asthma in
all patients.1,8 However, utilization of these medications is
suboptimal9,10 and adherence can also be poor, which can
limit the therapeutic outcomes.11
The Global Asthma Physician and Patient (GAPP)
Survey was the first global quantitative survey developed to
obtain the opinions on the management and treatment of
asthma from both physicians and patients.12 This survey
directly questioned physicians and patients from 16 countries
on asthma management practices, treatment patterns, adher-
ence to therapy, and opinions of current medication. Results
from the global GAPP Survey indicated that there is strong
relationship between a patient’s adherence to therapy and the
quality of physician-patient communication and the level of
medication side-effects.12 The global GAPP survey also
found that although ICS are indicated by the guidelines as
first-line therapy for asthma1,8 physicians tend to under-
prescribe ICS and may even prescribe long acting -agonists
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(LABAs) for mild persistent asthma for which the GINA and
NHLBI guidelines recommend ICS monotherapy.1,8,12 Be-
cause of country-specific social and health care environ-
ments, country-specific findings may differ from the global
GAPP results. This article presents the results from the US
subpopulation of the global GAPP Survey.
METHODS
The GAPP Survey was a large, global research study
conducted by Harris Interactive (Rochester, NY) between
May 18 and August 24, 2005 in 16 countries (Australia,
Belgium, Brazil, Canada, France, Germany, Ireland, Italy,
Japan, The Netherlands, Poland, Spain, Switzerland, South
Africa, the United Kingdom, and the US) on behalf of the
GAPP Survey global advisory board, which was comprised
of one member from the American College of Allergy,
Asthma and Immunology and 5 members from the World
Allergy Organization.12 The survey interviewed adults (18
years of age) with asthma, generalists (ie, family practitio-
ners, general practitioners, internists), and specialists (ie,
allergists and pulmonologists). For more details regarding the
global survey see Reference 12.
Sample size for the US was 200 asthmatic adults and
200 physicians. Patients with asthma were recruited by
phone from the Harris Interactive Inc.’s Chronic Illness and
Global Consumer Panels, in which several thousand patients
are registered.13 US physicians were recruited and surveyed
through Harris Interactive Inc.’s Online Physician Panel; this
panel includes every major medical specialty and is repre-
sentative of the US physician population by region, sex, and
medical specialty.13 Individuals were randomly selected from
these panels.
For this survey there was no specific approval or
informed consent. However, to be a member of the Harris
Interactive Inc.’s Chronic Illness and Global Consumer
Panels or Harris Interactive Inc.’s Online Physician Panel
required that participating patients and physicians consent
that their responses can be used in public as long as they
were presented in an aggregate, anonymous, and confiden-
tial fashion.
Physicians were included in the survey if they were
currently practicing medicine and had been doing so for 3 to
30 years, saw at least 3 adult asthma patients per week and
wrote at least one asthma medication prescription per week.
Patients had to have diagnosed asthma and be 18 years of
age, although, patients with chronic obstructive pulmonary
disease were not excluded.
The questionnaires were developed by the GAPP sur-
vey global advisory board. Before use the questionnaire was
tested on ten people in the US to ensure the content and
language of the questions were generally understood. Physi-
cians and patient respondents were questioned on topics
pertinent to asthma treatment using layperson and medical
language as appropriate and included physician prescribing
habits and beliefs, patient’s perception of their asthma, pa-
tient-doctor communication, and asthma medication issues.
Questions regarding demographic information were also in-
cluded to help further define and understand responses.
The number of interviews conducted was determined to
ensure statistical significance could be measured globally and
in each country for physicians and adult patients. Globally, a
total of 3459 interviews were conducted with 1733 physicians
and 1726 adult patients via the Internet, telephone, or in
person.12 Respondents from the US were questioned using
self-administered online interviews with close-ended question-
naires that took an average of 20 minutes to complete. The full
content of both questionnaires are provided as supplemental
material (see Tables 1 and 2; Supplemental Digital Content 1,
http://links.lww.com/WAOJOURNAL/A1).
Physician data were weighted by specialty, sex, and
years in practice to reflect the profile of physicians in the
American Medical Association. Patient data were weighted
by sex, education, age, household, income, and region to
reflect the adult asthma patient population from the National
Health Interview. With the number of physicians and patients
being 200 each, the sampling error for both groups was
3% and the margin of error was 7%.
RESULTS
In the US, 208 adults with asthma (mean age, 43.4
years) and 224 physicians (mean duration in practice, 15.5
years) responded to the questionnaire (Table 1). The rates
of response for physicians was 30% and for adults with
asthma 5%. The majority of participating physicians spe-
cialized in internal medicine (50%) or family medicine
(36%) (Table 1). The mean number of adult asthma patients
seen per week was 22.2, and the mean number of adult
asthma prescriptions written per week was 37.5 (Table 1).
The majority of patients were being treated by a primary care
physician (64%) (Table 1). Fifteen percent were being
treated by specialists (allergist or pulmonologist) and over
one-fifth (21%) were not having their asthma treated by
any physician or healthcare professional (Table 1; see Supple-
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mental Table 1, Q1a, Supplemental Digital Content 1,
http://links.lww.com/WAOJOURNAL/A1).
Impact of Asthma and Disease Control
Out of 208 adult patients interviewed 64% described
their asthma as mild, 30% as moderate, and 6% as severe
(Q2a). When asked whether asthma limited their daily activ-
ities, 38% of patients reported that it affected them ‘not at
all,’ 31% responded ‘not much,’ 30% ‘somewhat,’ and 2% ‘a
great deal’ (Q3a). Never-the-less, many of the patients may
not have had well-controlled asthma, as 20% of respondents
reported making an unscheduled telephone call to the doctor,
20% an unscheduled office visit, 6% an emergency depart-
ment visit, and 4% reported being admitted to hospital in
association with their asthma over the last year (Q4a).
Current Treatment
When patients were asked about which medications they
were currently receiving for their asthma, combination therapy
(an ICS plus a long-acting 2-agonist [LABA]), ICS mono-
therapy, and leukotriene receptor antagonists were reported
as being the most commonly used (29%, 27%, and 25%,
respectively), followed by LABAs (7%) and anticholinergics
(5%) (Q5a). Of patients interviewed, 30% also reported
receiving ‘other’ forms of medication (Q5a). For first-line
treatment, most physicians reported prescribing short acting
-agonists for all asthma severities and an ICS plus LABA
combination for moderate and severe persistent asthma (Fig. 1; see
Supplemental Table 2, Q1b, Supplemental Digital Content 1,
http://links.lww.com/WAOJOURNAL/A1). The majority of
physicians reported prescribing multiple medications for all
severities of asthma. Almost all the physicians “somewhat”
or “strongly” believed that treating inflammation reduced the
risk of bronchoconstriction (97%) and that ICS therapy was
the “gold standard” therapy for asthma (95%) (Q2b).
With regard to their current asthma treatments, 90%
of patients were satisfied with the ease of use and effective-
ness of the treatment, and 85% were satisfied with the
medication’s time to onset, safety, and dosing frequency
(Table 2; Q6a). Patients were least satisfied with the potential
for side effects of asthma medications. The greatest reason
for patients switching asthma medication was cessation or
reduction of symptoms, followed by experience of side ef-
fects (Fig. 2; Q7a).
Of the currently available drug treatments for asthma,
physicians were most satisfied with ICS and LABA combined
therapy, and least satisfied with mast-cell stabilizers and
immuno-therapy (Fig. 3; Q3b).
Most physicians in the survey reported asking patients
if there was an allergic component to their asthma: 98%
responded that they take a patient/family history of allergic
symptoms and 99% asked about their asthma triggers (Q4b).
Less than a third of the physicians tested for an allergic
component via skin prick (18%) or assayed the patient’s
blood for specific allergen-IgE (32%) (Q4b). Most physicians
(94%) reported that for patients with an allergic component to
their asthma the physicians incorporate allergen avoidance
into the asthma management plan, and 72% and 75% said
they explained that the patient should remain on controller
medication and referred the patient to an allergist or pulmo-
nologist, respectively (Q5b). About half the patients in the
survey with an allergic component to their asthma said that
their doctor explained how to avoid allergic triggers (59%)
and to use controller medication (50%) (Q8a). About a third
of these same patients (34%) reported being referred to an
allergist or other specialists (Q8a).





Family medicine 81 (36)
General practice 16 (7)
Internal medicine 112 (50)
Gender, n (%)
Male 152
Mean amount of time in clinical practice, years 15.5
Practice profile
Mostly office/clinic based, % 89





Mean number of adult patients/week, n 22.2





Mean age, years 43.4
Years since diagnosis, n (%)
5 38 (18)
5 to 10 38 (18)
10 to 15 37 (18)
15 to 20 35 (17)
20 to 30 27 (13)
30 33 (16)
TABLE 2. Patient Satisfaction With Current Asthma
Treatments
Property of Current Asthma Treatment Patients Satisfied (%)




Dosing frequency per day 84
Potential for side-effects 74
Patient question: Overall, how satisfied are you with the following features of your
current asthma medication or medications*?
*Nonspecific with regard to asthma medication.
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Asthma Education
Physicians and patients had differing views on the level
and content of education regarding asthma and its treatments.
Both patients and physicians responded that the treating
physician is primarily responsible for patient education re-
garding asthma (86% and 95%, respectively) (Q9a and Q6b).
Almost all the physicians (90%) in the survey responded that
they spend up to 50% of the office visit discussing correct
inhaler technique, development and execution of an individ-
ual management plan, and recognizing and monitoring symp-
toms (Fig. 4; Q7b). Only 2% of physicians said they spent no
time on asthma education. In contrast, 55% of patients re-
ported that up to half the office visit was spent on asthma
education and 38% said none of the visit was spent on
educational issues (Fig. 4; Q10a). Compared with physicians,
patients reported less discussion of issues such as monitoring
peak expiratory flow, proper inhaler technique, keeping daily
symptom/medication diaries, disease management plan, and
contacting patient support groups (Table 3; Q11a and Q8b).
An indication that patient education may be inadequate was
the finding that 40% of the patients responded that they did
not know that asthma attacks can be fatal in patients with
mild asthma (Q12a).
Impact and Awareness of Medication
Side Effects
Physician and patient perceptions of how frequently
they discuss short-term and long-term side effects of asthma
medication also differed. Both physicians and patients re-
ported themselves as the person who initiated the discussion
of side effects (85% for physicians and 62% for patients)
(Q13a and Q9b). Furthermore, 90% and 77% of physicians
reported sometimes or always discussing short-term and
long-term side effects, respectively (Fig. 5a; Q10b and
Q11b). In contrast, 25% and 28% of patients said that their
doctors sometimes or always discussed short- and long-term
side effects, respectively, of their asthma medication (Fig. 5a;
Q14a and Q15a).
Many patients were unaware of the potential side-
effects associated with ICS treatment (Q16a), which con-
trasted with physicians who answered that the majority of
patients knew about potential side-effects (Table 4; Q12b).
For example, while 39% of patients reported being unaware
of long-term side effects, physicians believed that only 6% of
patients were unaware. Similar discrepancies were also ob-
served with short-term and cortisol/hypothalamic-pituitary-
adrenal axis suppression (Table 4). Both patients and physi-
cians were moderately concerned with ICS associated side
effects (Table 4; Q17a and Q13b). Most physicians in this
survey (68%) reported that they always informed a patient
that they were being prescribed an ICS (Fig. 5b; Q14b), and
physicians perceived that patients were moderately concerned
about taking a steroid (mean value was 5.1 on a 1–10 scale
where “1” means “not at all concerned and “10” means
“extremely concerned”) (Q15b).
FIGURE 1. Asthma medications currently being prescribed by physicians as first-line therapy for differing severities of asthma.
Physician question: Which medication or medications* do you prescribe as first-line treatment for: 1) mild intermittent asth-
ma; 2) mild persistent asthma; 3) moderate persistent asthma; and 4) severe persistent asthma? *Physicians could provide
more than one medication as a first-line treatment for each severity of asthma.
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Physicians and patients differed in their perception of
how well patients recognize ICS-related side effects. Only
1% of patients interviewed said that they had experienced
adrenal (cortisol) suppression, 8% said they had experienced
long-term side effects, and 36% reported having short-term
side effects (Q18a). In contrast, 17% of physicians reported
that their patients had decreased cortisol production, 48%
said their patients had long-term side effects, and 92% said
their patients experienced short-term side effects (Q16b).
Patients stated that side effects resulting from asthma medi-
cation caused them to consider switching (29%) or to switch
medication (24%), consider skipping (26%) or skip doses
(19%), or consider stopping (21%) or stop taking the medi-
cation entirely (22%), or change dosage (26%) (Q19a).
Causes and Effects for Noncompliance
Perceptions of compliance differed between patients
and physicians. When queried regarding the percentage of
time they took their asthma medication according to their
doctor or healthcare professional instructions, 35% of pa-
tients said they were fully compliant, 32% said they were
compliant more than 50% of the time, and only 8% of
patients said they were never compliant (Q20a). However,
none of the physicians reported that their patients were fully
compliant, 54% said that their patients were at least 50%
compliant, and 5% said their patients were never compliant
(Q17b). There are multiple reasons patients reported for
being noncompliant; the most frequent responses were that
symptoms went away, they felt they didn’t need the medica-
tion that often, or they forgot to take the medication (Table 5;
Q21a). These were also the most important reasons that
physicians reported for lack of compliance by patients, but
physicians also included lack of insurance coverage or med-
ication expense (Table 5; Q18b). Reasons that physicians
reported for knowing if their patients were complying with
treatment regimen were: asking the patients (97%), knowing
if their symptoms are controlled (89%), being told by the
patient (88%), or they weighed the inhaler (5%) (Q19b).
Physicians and patients differed in their perspectives of
the consequences of non or partial adherence to treatment
regimens. For example, 69% and 58% of patients reported
increased symptoms and limited physical activity, respec-
tively (Table 6; Q22a) as the primary consequence of none or
partial adherence to treatment. Conversely, between 90%
and 100% of physicians believed that their patients who
were not 100% compliant experienced increased symp-
toms and limited physical activity (Table 6; Q20b). For
each category, a higher percentage of physicians versus
patients believed non or partial adherence had a detrimen-
tal effect, particularly regarding the frequency and severity
of exacerbations, frequency of rescue medication use,
nighttime awakenings, and increased physician visits and
hospitalizations (Table 6).
FIGURE 2. Reasons for patients switching asthma medications. Question: Since being diagnosed with asthma, have you ever
switched from one asthma medication to another or discontinued an asthma medication because . . . .?
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New Medications
When questioned about the need for a new asthma
medication, a similar percentage of patients (76%) and phy-
sicians (79%) thought that there was the need for a new
treatment option in the US (Q23a and Q21b). When describ-
ing the required attributes for a new ICS, patients and phy-
sicians cited a lower potential for long-term side effects,
efficacy equivalent to that of currently available ICS treat-
ments and reduced propensity for oropharyngeal side effects
(Q24a and Q22b). In addition, physicians thought the ability
of the medication to be delivered without a spacer and that it
have high lung deposition would be important treatment
characteristics of a new ICS.
DISCUSSION
The GAPP survey was designed to identify differences in
perspectives between physicians and patients on the treatment of
asthma.12 Overall, findings of the US subpopulation are consis-
tent with the global survey results. Barriers to successful asthma
treatment are created by notable differences between physician
and patient perceptions regarding asthma and its effective treat-
ment. The differences are particularly pronounced with regard to
asthma education, awareness of side effects, disease symptoms,
and adherence to asthma therapy.
The GINA1 and NHLBI8 guidelines recommend that
physicians and patients collaborate and work as a team to
ensure that patients are knowledgeable about the disease and
have the skills to successfully self-manage their disease. Both
the global12 and US results indicate that in general, there is
poor physician-patient partnership in treating the disease. The
physician-patient partnership in the US may be less adequate
than in other countries, as patients in the US reported that a
lower proportion of time was spent on asthma education
(16%) compared with the global survey patients (25%), and a
greater proportion of US patients reported not knowing that
an asthma attack could be fatal (40% vs 53%) (Table 7).
Similar to the global results,12 US-specific findings indi-
cate that there is a lack of asthma disease control (Table 7). Most
US patients surveyed reported having mild-to-moderate asthma
and that the disease had little influence on their daily activities.
However, about 20% reported an unscheduled telephone call to
the doctor, 20% reported an unscheduled office visit, and 6%
either reported to the emergency room or were hospitalized for
their asthma. Additionally, many patients underestimated their
condition, because about 21% of the patients reported not re-
ceiving medical attention for their asthma and about 40% did not
know that exacerbations in patients with mild asthma could be
fatal. Similar observations regarding suboptimal asthma control
have been noted in previous studies14–16 and may reflect a lack
of patient knowledge about their disease and the treatment
outcomes they can expect.
Global12 and US patients and physicians surveyed dif-
fered about their concern of ICS side effects (Table 7).
Patients were more concerned about long-term side effects
FIGURE 3. Average physicians satisfaction with currently available asthma treatments. Question: On a scale of 1–10 where
“1” means “extremely dissatisfied” and “10” means “extremely satisfied” how satisfied are you with these currently available
types of medications for treating asthma overall?
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and physicians were more concerned about short-term side
effects. Furthermore, only a few patients reported having
long-term (8%) or short-term (36%) side effects while phy-
sicians believed most of their patients taking ICS or ICS/
combination therapy had experienced long-term (48%) and
short-term (98%) side effects. Compared with other countries
in the survey, the US patients may be less cognizant of
asthma medication side-effects: US patients versus the global
survey patients were significantly less concerned about de-
creased cortisol production and long-term side effects (US
results were 3.9 and 5.1 and global findings were 5.0 and 6.2,
respectively, on a scale of 1–10 where “1” means not at all
concerned and “10” means extremely concerned).
The global12 and US findings indicate that compliance
to therapy is poor (Table 7). Both the global and US physi-
cians and patients reported that the most common reason for
noncompliance was lack of symptoms. ‘No symptoms, no
disease’ has previously been coined as a phrase when refer-
ring to patients’ misunderstanding of their condition.17
Self-medicating at a lower dose, forgetfulness, fear of
steroids and concern over side-effects were also identified by
physicians and patients as reasons for noncompliance. Such
barriers to compliance have previously been observed and are
believed to result from poor patient–physician communica-
tion regarding the disease and the long-term benefits of
controller therapy.14,17–21 In the US, physicians also reported
insurance coverage and drug expense as other reasons for
noncompliance.
Despite defining the reasons for poor compliance, pa-
tients and physicians surveyed both globally12 and in the US
observed that lack of compliance had serious consequences to
health, quality of life, and resulted in potentially life-threat-
ening exacerbations. Despite the fact that physicians and
patients do recognize the link between therapy and disease,
many patients still remain poorly controlled. Again, this may
reflect inadequate disease education and lack of patient-
FIGURE 4. Proportion of office visit devoted to asthma education. Patient Question: During a typical visit with your doctor
or health care professional, what percentage of the time do you or did you spend discussing how to improve techniques for
successful management of your asthma? Physician Question: During a typical patient visit, what percent of time do you or other
health professionals in your office spend on patient education regarding asthma?
TABLE 3. Asthma Education Issues Patients Discuss with
Their Health Care Providers
Patients Physicians
A plan for treating asthma 53% 87%
Correct inhaler technique 63% 95%
Keeping daily symptom/medication diaries 23% 50%
Monitoring peak expiratory flow 37% 84%
Contacting patient support groups 7% 26%
Patient question: Does your doctor or other healthcare professional in his or her
office discuss any of the following with you?
Physician question: Do you regularly discuss the following with your asthma
patients?
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physician communication. Treatment programs that actively
involve both patients and physicians improve tangible out-
comes for the patient (ie, decreased nighttime awakenings,
increased physical activity, etc), increase the patient’s under-
standing of the need to control their asthma effectively and
the positive effects of controller medication and improves
adherence.22–25
Both the global12 and US-specific results found that
most physicians (both 95%) recognize ICS as the “gold
standard,” and believe that if you treat the inflammation you
FIGURE 5. (A) Frequency of discussions about short- and long-term side effects of asthma medications. Physician questions:
When you prescribe asthma medications to your patients, how often do you discuss local side effects such as oral thrush, pharyngi-
tis or hoarseness? When you prescribe asthma medications to your patients, how often do you discuss the potential for systemic
side effects such as osteoporosis, cataracts or glaucoma? Patient questions: How often do you or did you discuss short-term side
effects of your asthma medication related to your mouth or throat—such as fungal infection, sore throat or hoarseness—with your
doctor or health care professional? How often do you or did you discuss long-term side effects of your asthma medication—such as
weight gain, weakening of the bones or changing bone density, cataracts or glaucoma—with your doctor or other health care pro-
fessional? (B) Frequency of physicians informing patients of being prescribed an ICS. When you prescribe inhaled corticosteroids
alone or in combination, on average, what percent of the time do you tell your patients that they will be taking a steroid?
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reduce the risk of bronchoconstriction. This is consistent with
the findings that ICS therapy (either mono- or combined) was
reported to be prescribed by the majority of physicians
surveyed globally12 and in the US (except for mild-intermit-
tent asthma for which the majority of physicians prescribe
short-acting -agonists). In both groups of physicians LABA/
ICS combination is the most common treatment (90%) for
moderate-to-severe asthma as recommended by the guide-
lines.1,8 Although both the global findings and US-specific
results found that the majority of patients and physicians were
satisfied with currently available asthma medication, they still
cited the need for a new asthma medication. Major attributes
cited for a new medication were lower potential for long-term
side effects, similar efficacy as those presently available, and
fewer side effects in the mouth and throat. Physicians also
noted that a new ICS should have high lung deposition.
There are several aspects of this study that should be
considered when interpreting the results. The range of asthma
severity of the patients interviewed in this survey is not
known. Asthma severity is known to influence the percep-
tions and behaviors of patients with regard to therapy, disease
knowledge, and adherence.11,19 The response rate for physi-
cians (30%) is within the range that is typical for surveys
performed by Harris Interactive, however, for patients the
response was low (5%). To correct for selection bias associ-
ated with the physician and patient samples, the data for both
the physician and patient were weighted so that the findings
are likely representative of the general population. For each
set of questions, the percent of patients responding in a
specific way that were seeing a specialist, primary care
physician, nurse, or not seeing anyone is not known. This
may influence the interpretation of some results because in
the global GAPP survey a patient’s response appeared to be
influenced in some cases by the type of doctor they were
seeing for their asthma care.12 In addition, it is important to
note that the physician population in the US subgroup may
have differed compared with the global population. A greater
percentage of physicians participating in the global survey
were pulmonologists (37%) compared with those participat-
ing in the US part of the survey (2%). In the US, the specialty
most represented in the survey was internal medicine (50%).
Overall the US-specific findings of the GAPP survey
are similar to those of the global12 and of the Australian
subpopulation26 of the GAPP survey. Key findings from all 3
sets of data indicate that in general there is a lack of asthma
control that likely results from poor adherence to therapy, and
may at least in part reflect poor patient-physician partnership
in treating this chronic disease. These findings are similar to
another large worldwide survey that aimed at determining
factors that influence asthma treatment.27
The US findings may suggest a need for improved
patient-physician partnership in the US and may support a













46 3.9 14 4.4
Long-term side
effects
39 5.1 6 5.1
Short-term side
effects
19 4.6 5 5.7
*The following is a list of potential side effects of inhaled corticosteroids. On a
scale of 1–10 where “1” mean “not at all concerned” and “10” means “extremely
concerned,” how concerned have you been with the following potential side effects, or
were you not previously aware of these as potential side effects?
†On a scale of 1–10 where “1” means “not at all concerned” and “10” means
“extremely concerned,” how concerned are your patients with each of the following
potential side effects of inhaled corticosteroids, or are they not aware of potential side
effects?
TABLE 5. Reasons Patients Fail to Comply With Asthma
Medication Treatment Regimen
Patients (%)* Physicians (%)†
Don’t need to take if symptoms
go away
5.4 7.9
Don’t need to take it so often 5.2 7.5
Forget 5.2 7.3
Fear of steroids 4.1 5.6











*Patient question: On a scale of 1–10 where “1” means “not at all important” and
“10” means “extremely important,” now important are the following reasons you don’t
or didn’t always take your asthma medication as instructed?
†Physician question: On a scale of 1–10 where “1” means not at all important” and
“10” means “extremely important,” how important are the following reasons your
patients don’t take their asthma medication as instructed?
TABLE 6. Patient and Physician Reported Consequence of
Patients Not Taking Medication
Patients (%)* Physicians (%)†
Increase symptoms 69 100
Limited physical activity 58 91
Increased use of bronchodilator 46 99
Nighttime awakenings 39 93
More frequent asthma attacks or
asthma exacerbations
35 100
More severe asthma attacks 27 94
More physician visits 25 99
More hospitalizations or ER
visits
13 90
Absence from work 10 87
Life-threatening asthma attacks 10 65
Less interaction with friends and
family
9 55
*Patient question: Have you ever experienced the following if you don’t or didn’t
take your asthma medication as instructed?
†Physician question: Among your asthma patients, does non-compliance in their
use of asthma medication cause . . . ?
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change in the US from a more physician-led, technology-
based, acute disease centered model of care to a more patient-
centered medical home model. The patient-centered medical
home model uses evidenced-based guidelines in treatment
decisions and ensures adequate patient communication with
healthcare professionals to help patients meet the challenges
of a chronic disease such as asthma.22,28,29 A central compo-
nent of the model is to improve chronic disease care through
a patient oriented intervention of an educational and support-
ive nature. This model stresses continuous relationships with
the care team, individualized care according to the patient’s
needs and values, anticipation of the patient’s needs, services
based on evidenced based guidelines and cooperation among
physicians.29 The model also uses regular contact of the
patient with the care team (through visits, email, phone calls,
etc) to reinforce the patient’s knowledge, self-management
skills and confidence to become more responsible for and
involved in their own disease management.29,30
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